New bioinformatics businesses bloomed over the past year in spite of a challenging market and encroachment from instrument vendors and other larger entities.
With their new collaboration, the parties look to put into more direct contact the research and implementation portions of the personalized medicine pipeline.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
Researchers saw higher-than-anticipated genetic diversity when they sequenced a handful of Plasmodium vivax isolates from a malaria endemic region in Colombia.
UK researchers have technically validated a qPCR testing method for a panel of four microRNAs with high sensitivity in diagnosing and monitoring rare tumors.
The US Department of Justice sued the company for paying doctors to perform its genomic tests, and then obtaining government reimbursements.
A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.
After falling for three years in a row, mergers and acquisitions in the omics space rose sharply in 2015, driven by a few billion-dollar-plus deals.
With ProteinPaint, investigators can visualize sequence mutations, gene fusions, and RNA expression to interpret patterns in germline and tumor samples.
The work offers a proof of concept for the notion that dynamic models of signaling could serve as more effective biomarkers than discrete molecular markers.
A study in the New England Journal of Medicine showing that NIPT outperformed standard screening for T21 topped the list of most-read stories in 2015.
The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.
The genetic evidence supports a link between migrations and important cultural shifts like the emergence of agriculture or metal tools occurring in parallel.
The company's stock faces a potential delisting from Nasdaq for failing to meet the stock exchange's $1 minimum bid price for 30 consecutive days.